Last reviewed · How we verify
Cetuximab injection
Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing growth signals and inducing cell death.
Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing growth signals and inducing cell death. Used for Metastatic colorectal cancer (KRAS wild-type), Head and neck squamous cell carcinoma, Non-small cell lung cancer.
At a glance
| Generic name | Cetuximab injection |
|---|---|
| Also known as | Erbitux |
| Sponsor | Shanghai Miracogen Inc. |
| Drug class | EGFR inhibitor monoclonal antibody |
| Target | EGFR (Epidermal Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cetuximab binds to EGFR with high affinity, competitively inhibiting ligand binding and preventing receptor activation. This blocks downstream signaling pathways (MAPK and PI3K/AKT) that drive cell proliferation and survival. The antibody also recruits immune cells to mediate antibody-dependent cellular cytotoxicity (ADCC) against EGFR-expressing tumor cells.
Approved indications
- Metastatic colorectal cancer (KRAS wild-type)
- Head and neck squamous cell carcinoma
- Non-small cell lung cancer
Common side effects
- Acneiform rash
- Diarrhea
- Nausea
- Fatigue
- Infusion reactions
- Hypomagnesemia
Key clinical trials
- A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (PHASE1)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (PHASE2, PHASE3)
- JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (PHASE3)
- Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PHASE2)
- IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation (PHASE2)
- A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
- A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cetuximab injection CI brief — competitive landscape report
- Cetuximab injection updates RSS · CI watch RSS
- Shanghai Miracogen Inc. portfolio CI